Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:9 Issue:8 Number:15 ISSN#:2564-2537
ACE Report #6335
Ace Report Cover Tumour

Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone

How to Cite

OrthoEvidence. Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone. ACE Report. 2020;9(8):15. Available from: https://myorthoevidence.com/AceReport/Report/6335

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500.

Contributing Authors: MR Smith S Halabi CJ Ryan A Hussain N Vogelzang W Stadler RJ Hauke JP Monk P Saylor N Bhoopalam F Saad B Sanford WK Kelly M Morris EJ Small

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Six hundred and forty-five patients with castration-resistant prostate cancer and bone metastases were randomized to either early administration of zoledronic acid or standard administration of zoledronic acid initiated following progression to castration-sensitive disease. The purpose was to determine whether early treatment would reduce time to developing a skeletal-related event (SREs) compared...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.